Long-term responders with metastatic breast cancer (MBC) receiving eribulin: Real life experience.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e13065
Abstract: e13065Background: Recently developed microtubule dynamics inhibitor eribulin mesylate (eribulin) differs from taxanes and vinca alkaloids by another mechanism of action. Here, we describe eribulin-... read more here.
Keywords: long term; breast cancer; term responders; metastatic breast ... See more keywords